Trial Profile
OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OCTOPUS
- 09 Dec 2019 Status changed from active, no longer recruiting to completed.
- 22 Aug 2018 According to The Institute of Cancer Research media release, the initial results of this trial are expected later this year.
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.